Cancer is one of the biggest burdens for so many public health departments across the world and China has even more cancer patients due to growing population at rapid pace. According to GLOBCAN, nearly 2.9 Million new cancer deaths happened in China in the year 2018. If we talk about cancer incidence, this rate is much lower in China rather than United States and United Kingdom. But when we talk about mortality rate, China mortality rate is almost 30% to 40% higher than the United States and United Kingdom. Moreover, increasing diagnostic center, improving cancer treatment therapy and acceptance of targeted drug therapy will further boost the China cancer market in forecast period. However, expensive cancer drug and various side-effects will also hinder the market. According to the publisher, Analysis, China Cancer Drug Market will surpass US$ 30.5 Billion by the year end of 2025.
China cancer drug market has grown rapidly in historical period and it is expected to grow significantly during the forecast period. There are various factors that will help the market to outperform; rising ageing population in China, changes of lifestyle and food habits, rising incidence rate of several type of cancer, rise in tobacco smoking population due to expansion of urbanization in China, improving healthcare infrastructure and facilities in China, increasing per capita disposable income, rising per capita healthcare expenditure, improving awareness regarding cancer risk, potential due to emerging economies etc.
This report titled “China Cancer Drugs Market, by Drugs [Cytotoxic Drugs (Antimetabolities, Plant Alkaloids, Alkylating Agents), Targeted Drugs, Monoclonal Antibiotics, Hormonal Drugs, Traditional Chinese Medicine (TCM), & Others], Cancer (Lung, Stomach, Breast, Esophageal, Liver & Others), Therapy (Chemotherapy, Targeted Therapy, Hormonal Therapy & Others), Companies (Merck, Celgene, Eli Lilly, Roche & Sino BioPharma)” provides a complete analysis of China Anti-Cancer Drugs Market.
China Cancer Drug Market Insight by Drug Type
In this report, China cancer drugs market is fragmented by drug type into six parts; Targeted Drugs, Cytotoxic Drugs, Monoclonal Antibiotics, Hormonal Drugs, TCM and Others. Cytotoxic Drugs type is further categorized into three parts; Antimetabolites, Plant Alkaloids and Alkylating Agents. Currently targeted drugs have more ability to kill malignant cells and it is quite popular because of higher success rate and efficacy.
China Cancer Drug Market Insight by Types of Cancer
In this report, we have done in-depth analysis of market by types of cancer; Lung, Stomach, Breast, Esophageal, Liver & Others.
China Cancer Drug Market Insight by Therapy
According to the publisher, targeted drug therapy is growing significantly in China due its higher efficacy and success rate than other therapy. In this report, we have design multi-dimensional approach to study all the cancer therapy which includes various important variables such as prime factors that support market growth, opportunities in each therapy, challenges faced by particular therapy etc.
By Drugs
- Cytotoxic Drugs
- Antimetabolities
- Plant Alkaloids
- Alkylating Agents
- Targeted Drugs
- Monoclonal Antibiotics
- Hormonal Drugs
- Traditional Chinese Medicine (TCM)
- Others
By Cancer
- Lung Cancer
- Stomach Cancer
- Breast Cancer
- Esophageal Cancer
- Liver Cancer
- Others
By Therapy
- Chemotherapy
- Targeted Therapy
- Hormonal Therapy
- Others
Companies Covered in the Report
- Merck
- Celegene
- Eli Lilly
- Roche
- Sino BioPharma
Table of Contents
Companies Mentioned
- Merck
- Celegene
- Eli Lilly
- Roche
- Sino BioPharma
Methodology
In this report, for analyzing the future trends for the studied market during the forecast period, the publisher has incorporated rigorous statistical and econometric methods, further scrutinized by secondary, primary sources and by in-house experts, supported through their extensive data intelligence repository. The market is studied holistically from both demand and supply-side perspectives. This is carried out to analyze both end-user and producer behavior patterns, in the review period, which affects price, demand and consumption trends. As the study demands to analyze the long-term nature of the market, the identification of factors influencing the market is based on the fundamentality of the study market.
Through secondary and primary researches, which largely include interviews with industry participants, reliable statistics, and regional intelligence, are identified and are transformed to quantitative data through data extraction, and further applied for inferential purposes. The publisher's in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. These analytical tools and models sanitize the data & statistics and enhance the accuracy of their recommendations and advice.
Primary Research
The primary purpose of this phase is to extract qualitative information regarding the market from the key industry leaders. The primary research efforts include reaching out to participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions. The publisher also established professional corporate relations with various companies that allow us greater flexibility for reaching out to industry participants and commentators for interviews and discussions, fulfilling the following functions:
- Validates and improves the data quality and strengthens research proceeds
- Further develop the analyst team’s market understanding and expertise
- Supplies authentic information about market size, share, growth, and forecast
The researcher's primary research interview and discussion panels are typically composed of the most experienced industry members. These participants include, however, are not limited to:
- Chief executives and VPs of leading corporations specific to the industry
- Product and sales managers or country heads; channel partners and top level distributors; banking, investment, and valuation experts
- Key opinion leaders (KOLs)
Secondary Research
The publisher refers to a broad array of industry sources for their secondary research, which typically includes, however, is not limited to:
- Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
- Patent and regulatory databases for understanding of technical & legal developments
- Scientific and technical writings for product information and related preemptions
- Regional government and statistical databases for macro analysis
- Authentic new articles, webcasts, and other related releases for market evaluation
- Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecasts
LOADING...
